Analysts expect over 2019 rising revenue Biogen

Tomorrow the American Biogen will report its past quarter results. Over the current book year the total revenue will be 14,17 billion USD (consensus estimates). This is slightly more than 2018's revenue of 13,45 billion USD.

Historical revenues and results Biogen plus estimates 2019

stock graphs

The analysts expect for 2019 a net profit of 6,12 billion USD. For this year most of the analysts expect a profit per share of 32,3 USD. So the price/earnings-ratio equals 6,81.

Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a moderate 1 percent.

Newest target prices around 268 USD

The most recent recommendations for the biotech company are from Oppenheimer & Co, Jefferies & Co. and Citigroup.

Based on the current number of shares Biogen's market capitalization equals 46,54 billion USD. The Biogen stock was the past 12 months quite volatile. Since last October the stock is 31 percent lower. This year the stock price moved between 216 and 344 dollar.

Historical stock prices Biogen from 2007 till 2019

stock graphs biogen

Click here for dividend . At 15.37 the stock trades 2,14 percent higher at 220,06 USD.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.